Vendor comparison · 2026
Tirzepatide vendors: 21 compared on COAs and price
MetabolicAlso known as GIP/GLP-1 dual agonist
Evidence tier
Regulator-reviewed human evidence
4 human trials · 1 review · approved counterpart
- Vendors carrying it
- 21
- 18 with a listed price
- Vendors with checkable COAs
- 12
- 12 publish any certificate
- Lots tested
- 40
- 39 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 15 Sept 2026
- oldest 7 Feb 2026
- Laboratories named
- 10
- most often ILS Laboratories
- Median label gap
- 5.5%
- 48% of lots within 5% of label
- Median purity
- 99.81%
- 40 of 40 lots at 99% or above
- Lowest price per mg
- $2.00
- peer median $6.75
- Publications located
- 2.3k
- researched since 2018
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Featured in the October 2026 peptide COA report →
Next Gen Peptides has the most checkable Tirzepatide testing in this index: 12 lots assayed by ILS Laboratories, the newest on 14 Sept 2026. The lowest listed price is $2.00 per mg at Next Gen Peptides, the same vendor, against a peer median of $6.75. 21 vendors carrying Tirzepatide are compared below. 12 publish at least one certificate naming a checkable laboratory, 40 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Tirzepatide
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 42.9% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $2.00 (30%) | 12 / 12 | ILS Laboratories | 99.9% | 5.3% | ||
| 3 | Ascend ScienceISO/IEC 17025 | 92.994% | $4.55 (67%) | 6 / 6 | Kovera Labs, Kovera Labs and/or ILS Labs | 99.7% | 3.7% | ||
| 4 | Amino ClubISO/IEC 17025Age-gated COAs | 92.598% | $2.00 (30%) | 0 | — | — | — | — | |
| 5 | Stealth Research Labs | 88.891% | $4.50 (67%) | 1 / 1 | Bioviridian Inc. | 99.8% | 2.6% | ||
| 6 | Bench Grade Peptides | 87.489% | $4.50 (67%) | 3 / 3 | AV Analytics, Freedom Diagnostics Testing | 99.8% | 3.7% | ||
| 7 | One Aminos | 8789% | $5.00 (74%) | 1 / 1 | United Laboratories | 99.7% | 2.9% | ||
| 8 | Northline LabsISO/IEC 17025 | 80.895% | $7.00 (104%) | 1 / 1 | Horizon Analytical | 99.3% | 2.2% | ||
| 9 | NeuroLabs Research | 80.191% | $7.00 (104%) | 1 / 1 | Freedom Diagnostics Testing | 99.5% | 34.9% | ||
| 10 | Ascension Peptides | 78.989% | — | 2 / 2 | MZ Biolabs | 99.9% | 13.1% | ||
| 11 | Hydro Research PeptidesISO/IEC 17025 | 73.489% | $8.50 (126%) | 6 / 7 | ILS Laboratories, Janoshik Analytical | 99.7% | 13.0% | ||
| 12 | Evo Labs Research | 71.687% | $7.00 (104%) | 0 | — | — | — | — | no reportVisit site |
| 13 | Koi PeptidesAge-gated COAs | 69.792% | $9.00 (133%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Disguised Alpha | 6966% | $3.17 (47%) | 0 | — | — | — | — | no reportVisit site |
| 15 | True Research Labs | 66.568% | $5.90 (87%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Evolve Peptides | 66.168% | $6.50 (96%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Prime PeptidesISO/IEC 17025 | 66.196% | $10.00 (148%) | 3 / 3 | Freedom Diagnostics Testing, Bioviridian Inc. | 99.9% | 8.6% | ||
| 18 | Protide HealthAge-gated COAs | 65.592% | $11.00 (163%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Good Science Bio | 60.871% | $9.00 (133%) | 0 | — | — | — | — | no reportVisit site |
| 20 | Improved Peptides | 57.887% | $9.90 (147%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Vertex Labs | 56.172% | — | 2 / 2 | Freedom Diagnostics Testing | 99.7% | 2.7% |
Independent assays
No independently commissioned assay of Tirzepatide is on file. All 40 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
40 of 40 lots at 99% or above; median 99.81%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 4 |
| ≥99.5% | 36 |
48% of lots within 5% of the labelled mass; median gap 5.5%.
| Range | lots |
|---|---|
| ≤2% | 2 |
| 2–5% | 17 |
| 5–10% | 10 |
| 10–20% | 9 |
| >20% | 2 |
18 vendors, $2.00 to $11.00; median $6.75.
| Range | vendors |
|---|---|
| $2.00–$4.00 | 3 |
| $4.00–$6.00 | 5 |
| $6.00–$8.00 | 4 |
| $8.00–$10.00 | 4 |
| $10.00–$12.00 | 2 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| ILS LaboratoriesUS | 17 | 2 | 43% | Public lookup |
| Freedom Diagnostics TestingUS | 7 | 5 | 18% | Public lookup |
| Kovera Labs | 5 | 1 | 13% | No public lookup found |
| AV Analytics | 2 | 1 | 5% | No public lookup found |
| Bioviridian Inc.US | 2 | 2 | 5% | Public lookup |
| MZ BiolabsUS | 2 | 1 | 5% | No public lookup found |
| Horizon Analytical | 1 | 1 | 3% | No public lookup found |
| Janoshik AnalyticalCZ | 1 | 1 | 3% | Public lookup |
| Kovera Labs and/or ILS Labs | 1 | 1 | 3% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 3% | Public lookup |
1 further record namesno checkable laboratory (a placeholder, a signature line or the vendor’s own name). It is listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2018 — 8 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
2,326 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.8% across 40 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.17 pts purity across lots, mean label deviation 8.3%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
21 of 21 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
39 of 40 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Tirzepatide?
A dual GIP and GLP-1 receptor agonist peptide. As with semaglutide, an approved pharmaceutical product exists; material listed by indexed vendors is research-grade powder and is not that product.
Studied in published research for type 2 diabetes and obesity / weight management.
Regulatory status
Approved as a prescription medicine in several jurisdictions. Research-grade material listed by indexed vendors is labeled for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
A published clinical literature exists for the approved pharmaceutical product. It does not transfer to research-grade material, whose identity and purity depend entirely on the certificate accompanying the lot.
- Tirzepatide for Obesity Treatment and Diabetes Prevention — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis — The New England journal of medicine (2024)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2024).
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial — JAMA (2024)
Peer-reviewed article indexed in PubMed, published in JAMA (2024).
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity — JAMA internal medicine (2024)
Peer-reviewed article indexed in PubMed, published in JAMA internal medicine (2024).
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial — Lancet (London, England) (2021)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2021).
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight — Diabetes, obesity & metabolism (2025)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2025).
- Tirzepatide: A Review in Type 2 Diabetes — Drugs (2024)
Peer-reviewed article indexed in PubMed, published in Drugs (2024).
Indexed studies5 human-evidence of 5
- Meta-analyses of GLP-1 receptor agonist trials — Meta-analysis
Pooled analyses of trials of approved GLP-1 receptor agonist products. Meta-analytic findings inherit the population and product of the trials they pool, and do not transfer to material obtained outside that supply chain.
- Randomised controlled trials of tirzepatide, the approved medicine — Human — controlled trial
Trial literature for the approved dual GIP/GLP-1 agonist product. As with semaglutide, the evidence attaches to the approved product rather than to research-grade powder of unverified identity.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity — Human — controlled trial, 2024
Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled…
- Tirzepatide Once Weekly for the Treatment of Obesity — Human — controlled trial, 2022
Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more a…
- Tirzepatide for Obesity Treatment and Diabetes Prevention — Human — controlled trial, 2025
Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. We perfor…
Evidence digest
What the research on Tirzepatide actually shows
The indexed literature on Tirzepatide includes human clinical or observational records (5 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Tirzepatide is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.